论文部分内容阅读
目的探讨阿托伐他汀联合吸入糖皮质激素治疗支气管哮喘的临床疗效。方法 74例慢性持续期支气管哮喘患者,随机分为观察组与对照组,各37例。对照组给予单纯吸入布地奈德治疗,观察组则给予阿托伐他汀联合吸入布地奈德治疗。比较两组治疗前后第1秒用力呼气容积占预计值百分比(FEV1%预计值)、呼气峰流速(PEF)、诱导痰嗜酸性粒细胞计数、外周静脉血免疫球蛋白E(Ig E)值。结果治疗后,观察组PEF、诱导痰嗜酸性粒细胞计数及外周静脉血Ig E值分别为(352±68)L/min、(0.032±0.011)×106/L、(77±32)KIU/L,均较对照组的(293±80)L/min、(0.041±0.012)×106/L、(110±60)KIU/L改善明显(P<0.05)。结论阿托伐他汀联合吸入糖皮质激素对支气管哮喘的治疗有积极效应。
Objective To investigate the clinical efficacy of atorvastatin combined with inhaled glucocorticoid in the treatment of bronchial asthma. Methods 74 patients with chronic persistent bronchial asthma were randomly divided into observation group and control group, 37 cases in each group. The control group received simple inhalation of budesonide, and the observation group received atorvastatin combined with budesonide. The ratio of forced expiratory volume to predicted value (FEV1% predicted), peak expiratory flow (PEF), induced sputum eosinophil count, peripheral venous blood IgE (E) value. Results After treatment, the values of PEF, induced sputum eosinophil count and peripheral blood IgE were (352 ± 68) L / min, (0.032 ± 0.011) × 106 / L and (77 ± 32) KIU / L were significantly higher than those in the control group (293 ± 80) L / min, (0.041 ± 0.012) × 106 / L and (110 ± 60) KIU / L, respectively. Conclusions Atorvastatin combined with glucocorticoid has a positive effect on the treatment of bronchial asthma.